2025-12-11 18:05
Infant Bacterial Therapeutics secures partnership with BioConnection for production of Drug Product
Infant Bacterial Therapeutics AB (IBT) whose mission is to develop and commercialize pharmaceuticals for diseases affecting premature babies and BioConnection...
Following today's meeting with the FDA concerning IBT's live biotherapeutic product, IBT has decided to pursue an accelerated approval pathway for IBP-9414...
2025-11-20 16:42
Infant Bacterial Therapeutics AB secures partnership with Recipharm Advanced Bio for production of drug substance
Infant Bacterial Therapeutics AB (IBT) and Recipharm Advanced Bio, a segment of Recipharm and a leading Contract Development and Manufacturing Organisation...
2025-11-13 07:30
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2025
Message from CEO The risk of death decreased by 27% for children who received our drug candidate IBP-9414 compared to placebo in our Phase 3 study. It...
2025-10-20 10:35
Infant Bacterial Therapeutics AB (publ) announces the appointment of the Nomination Committee for the Annual General Meeting 2026
The 2025 Annual General Meeting resolved that the Chairman of the Board shall convene the three largest shareholders in the company in terms of voting...
Communication with the FDA continues, and IBT is focused on obtaining drug approval for IBP-9414 in the US as soon as possible. The next step is a Pre-BLA...
2025-09-10 09:38
IBT presented “Avoiding the severe consequences of NEC” at the NEC Society Symposium in Chicago
Infant Bacterial Therapeutics AB (IBT) presented clinical outcomes following the administration of IBP-9414, an investigational Live Biotherapeutic Product...
Message from CEO IBT continues preparations for the launch of IBP-9414, a drug that can prevent the serious medical consequences of NEC in premature infants...
2025-05-14 07:30
Infant Bacterial Therapeutics (IBT) to present results of “The Connection Study” at ESPGHAN 2025 in Helsinki
Infant Bacterial Therapeutics (IBT) is pleased to announce that results from its pivotal Phase III trial, The Connection Study, will be presented at the...
2025-05-08 17:45
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2025, among other things, the following was resolved: ContactsStaffan...